Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05924633
Other study ID # LS-23-07-OSullivan
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 6, 2023
Est. completion date December 31, 2024

Study information

Verified date June 2023
Source University College Dublin
Contact Aifric O'Sullivan, PhD
Phone +353 1 716 2824
Email aifric.osullivan@ucd.ie
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized placebo-controlled study that aims to investigate the effect of a new maternal dietary supplement (protein hydrolysate/yeast beta-glucan combination) on mother and infant health.


Description:

N=140 healthy pregnant multiparous females aged between 18-49 years will be recruited to the study during pregnancy or up to 4-weeks postpartum, n=70 consuming the supplement and n=70 consuming a placebo. Following successful recruitment and screening, researchers will complete 2 study visits at the participant's home. Visit 1 marks the start of the intervention period and Visit 2 marks the end of the intervention period. Once the baseline data is completed (visit 1), the capsules will be provided to the mother. One capsule will be taken daily for 4 weeks. Capsules will be provided in convenient weekly tablet boxes. The return of used tablet boxes and counting missing capsules will monitor compliance. In addition, regular weekly contact will be maintained by phone and text message with participants to encourage adherence. In addition to the 2 study visits, all participants will receive an individual consultation with a lactation consultant to ensure breastfeeding techniques are appropriate and not a confounding factor in the breastmilk supply. Data collection will include: Anthropometric measurements include weight, height/length, and circumferences. Questionnaires will be used to collect birth data, demographic, lifestyle, breastfeeding and infant behavior, socio-economic status, health history, and gut health information. Dietary intakes will be assessed using an online 24-hour recall tool. Blood samples will be collected from mothers by a trained phlebotomist. A 5mL aliquot of breast milk will be collected from a full breast milk expression in the 24 hours prior to the research nurse visit using an electric breast pump. Mothers will record the volume of milk expressed and the remainder will be stored by the mother for the infant. for will use an electric breast pump for a full breast expression. The aliquot will be refrigerated until the research nurse visit. Mothers will collect a fecal sample from themselves and a fecal and urine sample from their baby in the 24 hours prior to the visit and will be stored in the freezer until the research nurse visit.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - Postpartum women aged 18-49 years - Multiparous with one previously breastfed child (defined as breastfed for greater than or equal to 3 months, does not need to be exclusively breastfed) - Delivered term - Woman free of breast or nipple infections - Woman willing to avoid other galactagogues/breastmilk supply stimulants while on study - Woman not taking medications that will affect lactation - Woman is the established carer for the infant - Infant has no baseline abnormality. Exclusion Criteria: - Less than 18 years old or older than 49 years (at time of recruitment) - Smokers - Individuals that are not free-living e.g. institutes where meals are prepared in bulk such as nursing homes, prisons etc. - An inability to read, write or understand English - Following a strict prescribed diet for any reason; insulin dependent diabetes, coeliac disease, Crohn's disease etc. as this may result in an altered gastrointestinal function. - Mother or child has a milk protein allergy - Covid-19 at very high-risk group (defined by HSE)

Study Design


Intervention

Dietary Supplement:
Supplement containing a protein hydrolysate + beta glucan (Wellmune®)
Supplement taken daily for 4 weeks.
Placebo supplement containing maltodextron
Placebo supplement taken daily for 4 weeks.

Locations

Country Name City State
Ireland University College Dublin Dublin

Sponsors (1)

Lead Sponsor Collaborator
University College Dublin

Country where clinical trial is conducted

Ireland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Expression of inflammatory cytokines in blood - TNF-alpha The effect of the dietary supplement on TNF-alpha expression in blood collected from mothers will be measured using a gene expression assay of more than 200 genes (e.g., IL-1, IL-6, IL-8, TNF-a) at baseline and endpoint (week 4). TNF-alpha expression will be measured as Ct values and reported as relative quantities. 4 weeks
Primary Expression of inflammatory cytokines in blood - IL-8 The effect of the dietary supplement on IL-8 expression in blood collected from mothers will be measured using a gene expression assay of more than 200 genes (e.g., IL-1, IL-6, IL-8, TNF-a) at baseline and endpoint (week 4). IL-8 expression will be measured as Ct values and reported as relative quantities. 4 weeks
Secondary Digestive health - SAGIS score The effect of the dietary supplement on the digestive health of the mother will be measured using the Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) questionnaire at baseline and endpoint (4 weeks). SAGIS assesses gastrointestinal symptoms using a Likert scale 0-4 which is summed to give the SAGIS score. 4 weeks
Secondary Markers of metabolic health in blood - glucose The effect of the dietary supplement on glucose concentrations (mmol/L) in blood collected from mothers will be measured using the HORIBA Pentra C400 at baseline and endpoint (week 4). 4 weeks
Secondary Markers of metabolic health in blood - insulin The effect of the dietary supplement on insulin concentrations (mU/L) in blood collected from mothers will be measured using the HORIBA Pentra C400 at baseline and endpoint (week 4). 4 weeks
Secondary Markers of metabolic health in blood - triacylglycerol The effect of the dietary supplement on triacylglycerol concentrations (mmol/L) in blood collected from mothers will be measured using the HORIBA Pentra C400 at baseline and endpoint (week 4). 4 weeks
Secondary Markers of metabolic health in blood - cholesterol The effect of the dietary supplement on cholesterol concentrations (mmol/L) in blood collected from mothers will be measured using the HORIBA Pentra C400 at baseline and endpoint (week 4). 4 weeks
Secondary Secretory IgA in breastmilk The effect of the dietary supplement on secretory IgA concentrations (ng/mL) in breastmilk collected from mothers will be measured using an ELISA at baseline and endpoint (week 4). 4 weeks
Secondary Breastmilk production volumn The effect of the dietary supplement on breastmilk production will be measured by a full breast expression (mL) at baseline and endpoint (week 4). 4 weeks
Secondary Expression of inflammatory cytokines in blood The effect of the dietary supplement on inflammatory cytokines in blood collected from mothers will be measured using a gene expression assay of more than 200 genes (e.g., IL-1, IL-6, IL-8, TNF-a) at baseline and endpoint (week 4). 4 weeks
Secondary Microbiota profile in feces The effect of the dietary supplement on the gut microbiota profile of fecal samples collected from mothers and infants. Gut microbiota will be profiled using 16S rRNA sequencing and QIIME software at baseline and endpoint (week 4). 4 weeks
Secondary Microbiota profile in breastmilk The effect of the dietary supplement on the gut microbiota profile of breastmilk samples collected from mothers. Microbiota will be profiled using 16S rRNA sequencing and QIIME software at baseline and endpoint (week 4). 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT00579605 - Motivational Interviewing to Promote Sustained Breastfeeding N/A
Completed NCT05655364 - Development of a Breastfeeding Supportive Mobile Application N/A
Completed NCT03853850 - Using Mobile Phone Text Messaging System to Improve Exclusive Breastfeeding Rate in a Resource-poor Caribbean Island N/A
Completed NCT03957941 - FamilyLink and Breastfeeding N/A
Withdrawn NCT03709004 - Pacifiers and Breastfeeding Among Mothers at Risk for Postpartum Depression N/A
Completed NCT02958475 - Mother's Milk Messaging: Evaluation of a Bilingual Application (APP) to Support Initiation and Exclusive Breastfeeding in New Mothers N/A
Active, not recruiting NCT05503069 - Community Interventions to Improve Breastfeeding N/A
Not yet recruiting NCT02233439 - Double-blind, Placebocontrolled A Randomized Trial on the Efficacy of Herbal Galactogogues N/A
Completed NCT01893736 - Professional Breastfeeding Support Intervention N/A
Completed NCT02738957 - Effect of Prenatal Counseling on Breastfeeding Rates in Twins N/A
Completed NCT00527956 - Facilitation and Barriers to Breastfeeding in the NICU N/A
Completed NCT03655314 - Using the Electronic Health Record to Guide Management of Newborn Weight Loss N/A
Completed NCT05562245 - Motivational Interviewing-Based Breastfeeding Education N/A
Completed NCT05106634 - Evaluation of Breastfeeding Success and Self-Efficacy in Mothers Giving Birth Via Vaginal Delivery or Cesarean Section
Completed NCT05992753 - Mothers' Breast Milk Expression Experiences, Infant Feeding Attitudes and Perceived Social Support Levels
Recruiting NCT05213975 - Kinesio Taping Application After Cesarean Section N/A
Recruiting NCT05250219 - Microchimeric Cell Tranfer From Mother to Child - Pilo Study
Recruiting NCT05371106 - Mycotoxins in Mothers Milk in Israel
Completed NCT03332108 - Novel Approach To Improving Lactation Support With Mobile Health Technology N/A
Completed NCT02901665 - Impact of Increased Parent Presence in the Neonatal Intensive Care Unit on Parent & Infant Outcomes N/A